IP Library Granted Patent US 11,180,765
Granted Patent B2
US 11,180,765 · App. 16/990,033 · Granted Nov 23, 2021

Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

Inventors: Roy Curtiss, III (Gainesville, FL); Shifeng Wang (Gainesville, FL); Soo-Young Wanda (Gainesville, FL); Wei Kong (Phoenix, AZ)
Assignees: The Arizona Board of Regents for and on behalf of Arizona State University; The Washington University
C12N15/74A61K35/74A61K39/00C12N1/36A61K2035/11A61K2039/522A61K2039/523
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,180,765
App. No.
16/990,033
Granted
Nov 23, 2021
Kind
B2
Abstract

The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Claims (23)

1. A recombinant bacterium capable of regulated expression of at least one nucleic acid sequence encoding a protein of interest, wherein the bacterium comprises:

a. at least one chromosomally integrated nucleic acid sequence encoding a repressor operably linked to a regulatable promoter, wherein the nucleic acid sequence encoding the repressor and/or promoter have been modified from the wild-type nucleic acid sequence so as to optimize the expression level of the nucleic acid sequence encoding the repressor;

b. a vector comprising at least one nucleic acid sequence encoding a protein of interest operably linked to a promoter regulated by the repressor, such that the expression of the nucleic acid sequence encoding the protein is repressed during in vitro growth of the bacterium, but the bacterium is capable of high level expression of the nucleic acid sequence encoding the protein in a host; and

c. the mutation ΔrelA198::araC P BAD lacI TT.

2. The recombinant bacterium of claim 1 , wherein the bacterium further comprises a deletion in asd.

3. The recombinant bacterium of claim 1 , wherein the bacterium further comprises the mutation ΔasdA::TT araC PBAD c2.

4. The recombinant bacterium of claim 1 , wherein the repressor is selected from the group consisting of LacI, C2, and C1.

5. The recombinant bacterium of claim 1 , wherein the nucleic acid sequence encoding the repressor comprises a modified Shine-Dalgarno sequence and optimized codons so as to optimize the expression level of the nucleic acid sequence encoding the repressor.

6. The recombinant bacterium of claim 1 , wherein the vector is a plasmid.

7. The recombinant bacterium of claim 1 , wherein the nucleic acid encoding the protein of interest is operably linked to a Ptrc promoter.

8. The recombinant bacterium of claim 1 , wherein the protein of interest is toxic.

9. The recombinant bacterium of claim 1 , wherein the vector further comprises a nucleic acid sequence encoding a secretion signal for the protein of interest.

10. The recombinant bacterium of claim 1 , wherein the bacterium is capable of eliciting a protective immune response in the host.

11. The recombinant bacterium of claim 1 , wherein the bacterium comprises more than one means of attenuation.

12. The recombinant bacterium of claim 1 , wherein

the repressor is LacI;

the regulatable promoter is selected from the group consisting of P rhaBAD , P xyIAB , and P xyIFGH ;

the vector is a plasmid; and

the nucleic acid sequence encoding the protein of interest is operably linked to the Ptrc promoter.

13. The recombinant bacterium of claim 1 , further comprising a deletion in pabA and/or a deletion in pabB.

14. A composition comprising the recombinant bacterium of claim 1 .

15. A method for ameliorating one or more symptoms of a disease in a host, the method comprising administering to the host an effective amount of the composition of claim 13 .

16. A method for eliciting an immune response in a host, the method comprising administering to the host an effective amount of the composition of claim 13 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2021
From: CURTISS, ROY, III; WANG, SHIFENG; WANDA, SOO-YOUNG; KONG, WEI
To: THE ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY; THE WASHINGTON UNIVERSITY
Reel/Frame 056855/0647 →
Continuity (8)
Continuation 16704032 · Dec 5, 2019
Continuation 15850957 · Dec 21, 2017
Continuation 15040005 · Feb 10, 2016
Continuation 13789665 · Mar 7, 2013
Continuation 12615872 · Nov 10, 2009
Continuation In Part PCTUS2008063293 · May 9, 2008
Provisional Application 60917313 · May 10, 2007
Related Publication 20200377897A1 · Dec 3, 2020